Shamburg News · 8-K filed Oct 30, 2026, 8:02 AM EDT
Azenta Enters Elegen License and Supply Agreements and Acquires SynPlexity
AZTA · Azenta, Inc.
- Material agreement
- Acquisition
- Reg FD disclosure
- Other event
- Materiality: high
On October 28, 2026, Azenta, Inc. entered into a License Agreement and a Master Services and Supply Agreement with Elegen Corp. granting an exclusive, royalty-free license to certain gene synthesis products for its GENEWIZ business, with aggregate capital deployment expected at approximately $32 million to $71 million. The same day, Azenta acquired all outstanding capital stock of SynPlexity Inc., a DNA assembly technology company, under a Stock Purchase Agreement that closed concurrently with signing. The Company issued a press release on October 30, 2026, announcing the transactions, furnished as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 8.01, 9.01, accession 0001628280-26-068443.
Written from the filing by Shamburg Markets. Figures are as reported by the company.